Ultromics is a global health technology firm which provides autonomous echocardiography analysis through innovative AI solutions empowering physicians to make fast, accurate decisions when diagnosing cardiovascular disease.
We have developed EchoGo, the world’s first autonomous echocardiography service which provides cloud-based artificial intelligence services to support cardiac imaging diagnosis without any variability or need to touch software.
Our technology was born at the University of Oxford and built in partnership with the NHS, and has since raised over £20 million to help improve patient care, and bring diagnostic quality and resource savings to hospitals. Cardiovascular disease is the leading cause of mortality, with an estimated 17 million deaths each year.
Ultromics was founded in May 2017 at the University of Oxford by Ross Upton and Professor Paul Leeson
While pursuing his PhD at the University of Oxford, Ross worked with Professor Leeson, Consultant Cardiologist and Head of the Oxford Cardiovascular Research Facility, to develop the world’s ﬁrst outcomes-driven, AI-based ultrasonic diagnostic support solution for coronary artery disease (CAD)*
During development, the team assembled and analyzed 120,000 echocardiographic images from clinical trials conducted at the University of Oxford. The team then tracked patient progress throughout the following year, collecting crucial longitudinal data specifying patient outcomes
Recognizing the significance of this breakthrough, the American Society of Echocardiography named Ultromics a part of the 2018 “Echovation Honor Roll”
Ultromics has attracted a team of clinicians, scientists, engineers, and healthcare professionals to develop, refine, and deliver our technology to market. A number of notable companies and individuals have also joined Ultromics as trusted partners